Medicure, Inc. (MPH) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

Shareholding (May 2014)

FII

0.01%

Held by 1 FIIs

DII

99.99%

Held by 0 DIIs

Promoter

0.00%

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Poor Management Efficiency with a low ROE of 0.78%

The company has been able to generate a Return on Equity (avg) of 0.78% signifying low profitability per unit of shareholders funds

The company has declared Negative results for the last 5 consecutive quarters

Risky -

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CAD 11 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.23

Return on Equity

-17.55%

Price to Book

0.62

Revenue and Profits:

Net Sales:

7 Million

(Quarterly Results - Jun 2025)

Net Profit:

-1 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

1.52%

6 Months

26.42%

1 Year

36.73%

2 Years

-15.72%

3 Years

16.52%

4 Years

44.09%

5 Years

61.45%

Medicure, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

9.59%

EBIT Growth (5y)

10.58%

EBIT to Interest (avg)

-2.20

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.34

Sales to Capital Employed (avg)

1.07

Tax Ratio

17.29%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.01%

ROCE (avg)

1.01%

ROE (avg)

0.78%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.63

EV to EBIT

-2.40

EV to EBITDA

-7.22

EV to Capital Employed

0.51

EV to Sales

0.31

PEG Ratio

Dividend Yield

ROCE (Latest)

-21.43%

ROE (Latest)

-17.55%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

Bearish

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : May 2014

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.01%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 21.82% vs -6.78% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -14.29% vs -16.67% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "6.70",
          "val2": "5.50",
          "chgp": "21.82%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.10",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.80",
          "val2": "-0.70",
          "chgp": "-14.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-104.80%",
          "val2": "-119.40%",
          "chgp": "1.46%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.92% vs -6.06% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -11.11% vs -164.29% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "21.90",
          "val2": "21.70",
          "chgp": "0.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.40",
          "val2": "1.30",
          "chgp": "-130.77%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "1.90",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.00",
          "val2": "-0.90",
          "chgp": "-11.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-124.90%",
          "val2": "-39.40%",
          "chgp": "-8.55%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

6.70

5.50

21.82%

Operating Profit (PBDIT) excl Other Income

-0.10

-0.00

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-0.80

-0.70

-14.29%

Operating Profit Margin (Excl OI)

-104.80%

-119.40%

1.46%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 21.82% vs -6.78% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -14.29% vs -16.67% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

21.90

21.70

0.92%

Operating Profit (PBDIT) excl Other Income

-0.40

1.30

-130.77%

Interest

0.00

Exceptional Items

1.90

0.00

Consolidate Net Profit

-1.00

-0.90

-11.11%

Operating Profit Margin (Excl OI)

-124.90%

-39.40%

-8.55%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.92% vs -6.06% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -11.11% vs -164.29% in Dec 2023

All Annual Results

Company CV

About Medicure, Inc.

Medicure, Inc.

Pharmaceuticals & Biotechnology

Medicure Inc. (Medicure) is a pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. The Company operates in the biopharmaceutical industry segment. The Company's primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc. and distributed in the United States and its territories through the Company's United States subsidiary, Medicure Pharma, Inc. AGGRASTAT, a glycoprotein IIb/IIIa inhibitor (GPI), is used for the treatment of acute coronary syndrome (ACS). The Company is also engaged in the development of TARDOXAL for neurological disorders, such as Tardive Dyskinesia (TD). The Company has completed Phase IIa stage of development for TARDOXAL. The Company is also developing Transdermal AGGRASTAT, a cure for acute cardiology. Transdermal AGGRASTAT is in preclinical-stage of development.

Company Coordinates

Company Details

1250 Waverley St Suite 2 , WINNIPEG MB : R3T 6C6

Tel: 1 204 4877412

http://www.medicure.com/

Registrar Details